Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 4/2012

01.10.2012

Insomnia Pharmacotherapy

verfasst von: Timothy Roehrs, Thomas Roth

Erschienen in: Neurotherapeutics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

The benzodiazepine receptor agonists (BzRAs) a melatonin receptor agonist and a histamine antagonist have all been approved as hypnotics. Beyond their differing mechanisms of action, they have differences in pharmacokinetics, and among the BzRAs differences in receptor subtype affinity and formulations, which provides the physician with broad options for tailoring therapy to each patient’s specific needs. Consistent with their specific pharmacokinetics and formulations, these Food and Drug Administration-approved hypnotics have been shown to improve sleep with no evidence of tolerance development in long-term use. In addition, emerging data indicate these drugs also improve aspects of daytime function. Their side effects are either associated with the direct sedating effects of the drugs, doses greater than clinical doses, or a combination with alcohol or other sedating drugs. Anxiolytic BzRAs, sedating antidepressants and antipsychotics have been used off-label as hypnotics. However, in the absence of information regarding their dose range for efficacy and safety, their use as hypnotics is ill-advised.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Gallup. Sleep in America. Princeton: Gallup, 1995:1–78.
2.
Johnson EO, Roehrs T, Roth T, et al. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998;21:178–186.PubMed
3.
Roehrs T, Hollebeek E, Drake C, et al. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 2003;53:571–576.CrossRef
4.
Roehrs T, Roth T. Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev 2001;5:287–297.PubMedCrossRef
5.
National Institutes of Health. State of the science conference statement on manifestations and management of chronic insomnia in adults June 13-15, 2005. Sleep 2005;28:1049–1057.
6.
Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2–8.PubMedCrossRef
7.
Mendelson WB, Thompson C, Franko T. Adverse reactions to sedative hypnotics: three years’ experience. Sleep 1996;19:702–706.PubMed
8.
Nutt D. GABA-A receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2006;2:S7–S11.PubMed
9.
Fava M, Schaefer K, Huang H, Wilson A, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiat 2011;72:473–479.CrossRef
10.
Pollack M, Kinrys G, Krystal A, et al. Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiat 2009;65:551–562.CrossRef
11.
Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiat 2011;72:914–928.CrossRef
12.
Fava M, Asnis GM, Shrivastava R, Lydiard B, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharm 2009;29:222–230.CrossRef
13.
Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170–2177.PubMedCrossRef
14.
Holbrook AM, Crowther R, Lotter A, et al. Meta-anlysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000;162:225–233.
15.
Merlotti L, Roehrs T, Koshorek G, Zorick F, Lamphere J, Roth T. The dose effects of zolpidem on the sleep of healthy normals. J of Clin Psychopharm 1989;9:9–14.
16.
Lamphere JK, Roehrs TA, Zorick FJ, Koshorek G, Roth T. The dose effects of zopiclone. Hum Psychopharm 1989;4:41–46.CrossRef
17.
Roth T, Hull SG, Lankford DA, et al. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night [MOTN] awakenings. Sleep 2008;31:277–1284.
18.
Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, doubled blinded, placebo controlled study in adults with chronic insomnia. Sleep 2003;26:793–799.PubMed
19.
Walsh JK., Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effects on sleep, quality of life, and work limitations. Sleep 2007;30:959–968.PubMed
20.
Randall S, Roehrs T, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo controlled study. Sleep (in press).
21.
Karin A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of remelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006;46:140–148.CrossRef
22.
Roth T, Roehrs T. Issues in the use of benzodiazepine therapy. J Clin Psychiatry 1992;53:S14–S18.
23.
Mendelson WB, Thompson C, Franko T. Adverse reactions to sedative/hypnotics: three years’ experience. Sleep 1996;9:702–706.
24.
Rush CR, Griffiths RR. Zolpidem, triazolam and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;6:46–57.
25.
Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory and performance effects of hypnotics. Psychpharmacology [Berl] 1994;16:30–34.
26.
Danjou P, Fruncillo PR, Worthington P, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999;48:367–374.PubMedCrossRef
27.
Carskadon MA, Seidel WF, Greenblatt DJ, et al. Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep 1982;5:362–371.
28.
29.
Kelly KD, Pickett W, Yiannakaoulias N, et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003;32:503–509.PubMedCrossRef
30.
Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003;163:949–957.PubMedCrossRef
31.
Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Ger Soc 2000;48:1234–1240.
32.
Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD. Insomnia and hypnotic use recorded in the minimum data set as predictors of fall and hip fractures in Michigan nursing homes. J Am Ger Soc 2005;53:955–962.CrossRef
33.
Roehrs T, Zorick F, Sicklesteel J, et al. Effects of hypnotics on memory. J Clin Psychopharmacol 1983;3:310–313.PubMed
34.
Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology [Berl] 1996;128:67–73.CrossRef
35.
Mohler H, Crestani F, Rudolph U. GABA-A receptor subtypes: a new pharmacology. Curr Opin Pharmacol 2001;1:22–25.PubMedCrossRef
36.
Guillmineau C, Dement WC. Amnesia and disorders of excessive sleepiness. In: Drucker-Colin RR, McGaugh JL, eds. Neurobiology of sleep and memory. London: Academic Press, 1977.
37.
Roehrs TA, Vogel G, Roth T. Rebound insomnia: Its determinants and significance. Am J Med 1990;88:43S–46S.PubMed
38.
Roehrs T, Zorick F, Wittig R, et al. Dose determinants of rebound insomnia. Brit J Clin Pharmacology 1986;22:143–147.CrossRef
39.
Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharm 2012;26:1088–1095.
40.
Merlotti L, Roehrs T, Zorick F, et al. Rebound insomnia: duration of use and individual differences. J Clin Psychopharm 1991;11:368–373.CrossRef
41.
Roehrs T, Merlotti L, Zorick F, et al. Rebound insomnia and hypnotic self administration. Psychopharmacology 1992;107:480–484.PubMedCrossRef
42.
Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology 1995;118:103–107.
43.
Kan CC, Hilldebrink SR, Breteier MHM. Determination of the main risk factors for benzodiazepine dependence using a multidimensional approach. Compr Psychiatry 2004;45:88–94.PubMedCrossRef
44.
Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Arch Gen Psychiatry 1985;42:225–232.PubMedCrossRef
45.
Roehrs T, Pedrosi B, Rosenthal L, et al. Hypnotic self administration and dose escalation. Psychopharmacology [Berl] 1996;127:150–154.CrossRef
46.
Roehrs T, Bonahoom A, Pedrosi B, et al. Nighttime versus daytime hypnotic self-administration. Psychopharmacology 2002;161:137–142.PubMedCrossRef
47.
Roehrs T, Bonahoom A, Pedrosi B, et al. Disturbed sleep predicts hypnotic self administration. Sleep Med 2002;3:61–66.PubMedCrossRef
48.
Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep 2011;34:201–212.
49.
Roth T, Singh NN, Steinbert FJ, Rosenberg R, Krystal A. Absence of tolerance, dependence potential, and rebound during PRN treatment of middle-of-the-night awakening with zolpidem tartrate sublingual tablet 3.5 MG. Sleep Med 2011;12(suppl 1):S58.CrossRef
50.
Roth T, Zammit GK, Scharf MB, Farber R. Efficacy and safety of as-needed, post bedtime dosing with Indiplon in insomnia patients with chronic difficulty maintaining sleep. Sleep 2007;30:1731–1738.PubMed
51.
Lisko B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry 2004;43:927–928.CrossRef
52.
Menkes DB. Triazolam-induced nocturnal bingeing with amnesia. Aust N Z J Psychaitry 1992;26:320–321.CrossRef
53.
Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323–327.PubMedCrossRef
54.
Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem – sleepwalking: a case report. Arch Phys Med Rehabil 2005;86:1265–1266.PubMedCrossRef
55.
Lange CL. Medication-associated somnambulism. J Am Acad Child Adoles Psychiatry 2005;44:211–212.CrossRef
56.
Lauerma H. Nocturnal wandering caused by restless legs and short-acting benzodiazepines. Acta Psychiatr Scand 1991;83:492–493.PubMedCrossRef
57.
Roehrs TA, Roth T. Safety of insomnia pharmacotherapy. Sleep Med Clinics 2006;1:399–407.CrossRef
58.
Kato K, Hirai K, Nichiyama K, et al. Neurochemical properties of ramelteon [TAK-375], a selective MT1 and MT2 receptor agonist. Neuropharmacology 2005;48:301–310.PubMedCrossRef
59.
Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of remelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24.PubMedCrossRef
60.
Roth T, Seiden D, Saimati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312–318.PubMedCrossRef
61.
Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005–1014.PubMedCrossRef
62.
Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495–504.PubMed
63.
Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32:351–360.PubMed
64.
DeMicco M, Wang-Weigand S, Zhang J. Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1 year study. Sleep 2006;29(suppl):A234.
65.
Richardson GS, Zee PC, Wang-Weigand S, et al. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med 2008;4:456–461.PubMed
66.
Roth T, Stubbs C, Walsh J. Ramelteon [TAK-375], a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303–307.PubMed
67.
Griffiths R, Suess P, Johnson M. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep 2005;28:A44.
68.
Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312–318.PubMedCrossRef
69.
Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 2005;28(suppl):A228–A229.
70.
Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149–1157.PubMedCrossRef
71.
Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453–463.PubMedCrossRef
72.
Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555–1561.PubMed
73.
Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557–1564.PubMedCrossRef
74.
Owen RT. Selective histamine H[1] antagonism: a novel approach to insomnia using low-dose doxepin. Drugs Today 2009;45:261–267.PubMedCrossRef
75.
Wolf B, Guarino JJ, Preston KL, Griffiths RR. Abuse liability of diphenhydramine in sedative abuser. NIDA Res Monogr 1989;95:486–487.PubMed
76.
Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27:1441–1442.PubMed
77.
Jenck F, Moreau JL, Mutel V, et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993;231:223–229.PubMedCrossRef
78.
Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(suppl A):34–39PubMed
79.
Montgomery I, Oswald I, Morgan K, et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139–144.PubMedCrossRef
80.
Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998:13:191–198.CrossRef
81.
Golden RN, Dawkins K, Nicholas L. Trazadone and nefazodone. In: Schatzberg A, Nemeroff C, eds. The American Psychiatric Textbook Of Psychopharmacology. Washington, DC: American Psychiatric Textbook, Inc., 2004:315–325.
82.
Levenson JL. Prolonged QT interval after trazodone overdose. Am J Psychiatry 1999;156:969–970.PubMed
83.
Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994;4:331–355.PubMedCrossRef
84.
Wiegard M, Landry T, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology 2008;196:337–338.CrossRef
85.
Juni C, Chana P, Tapia J, et al. Quetiapine for insomnia in Parkinson Disease: results from an open-label trial. Clin Neuropharmacol 2005;28:185–187.CrossRef
86.
Estivill E, de la Fuente V, Segarra F, et al. The use of olanzapine in sleep disorders. An open trial with nine patients. Rev Neurol 2004;38:829–831.PubMed
87.
Cates ME, Jackson CW, Feldman JM, et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009;45:251–254.PubMedCrossRef
88.
Roehrs T, Roth T. “Hypnotic” prescription patterns in a large managed-care population: Sleep Med 2004;5:463–466.PubMedCrossRef
89.
Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411–418.PubMedCrossRef
90.
Perlis ML, Giles DE, Buysse DJ, et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 1997;42:209–212.PubMedCrossRef
91.
Hall RC, Platt DE. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics 1999;40:18–27.PubMedCrossRef
92.
Roehrs TA. Does effective management of sleep disorders improve pain symptoms? Drugs 2009;69:S5–S11.CrossRef
93.
Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53–58.PubMed
94.
Walsh JK, Roth T, Randazzo AC, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23:1087–1096.PubMed
95.
Roehrs T, Bonahoom A, Pedrosi B, Rosenthal L, Roth T. Treatment regimen and hypnotic self-administration. Psychopharmacology 2001;155:11–17.PubMedCrossRef
96.
Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097–1104.PubMed
97.
Landolt HHP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999;21:455–466.PubMedCrossRef
Metadaten
Titel
Insomnia Pharmacotherapy
verfasst von
Timothy Roehrs
Thomas Roth
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Neurotherapeutics / Ausgabe 4/2012
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-012-0148-3

Weitere Artikel der Ausgabe 4/2012

Neurotherapeutics 4/2012 Zur Ausgabe

ReviewPaper

New and Unconventional Treatments for Obstructive Sleep Apnea

Original Article

Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology

ReviewPaper

Parasomnias: An Updated Review

ReviewPaper

Surgical Therapy of Obstructive Sleep Apnea: A Review

ReviewPaper

A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes

ReviewPaper

Strategies for the Treatment of Restless Legs Syndrome

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise